Medicare Monday: What does Medicare Part B Cover?

You’ve probably heard the Medicare alphabet before: Part A, Part B, Part D and more. But what does all of it mean? We talk a lot about the Medicare Part D prescription drug benefit here on Medicare...
Read More
10 Years Later: Lessons Learned from Hurricane Katrina

Ten years ago today I was lucky to have evacuated from New Orleans to Atlanta and sat waiting to see what would happen with the storm of the century. Having evacuated countless times before, I could...
Read More
Week in Review: The Latest from PhRMA

Developing New Medicines: Innovative medicines offer hope to patients and bring value to the health care system, but developing these new treatments is a rigorous, lengthy and costly process, and...
Read More
Free Trade Agreements May Be Good For Your Health

A new report by the Geneva Network titled “Trading for Health: Quantifying the Impact of Free Trade Agreements on Health Outcomes” recently called into question many claims being made by groups...
Read More
Ask About Adherence: Q&A with The Peter Lamy Center for Drug Therapy and Aging

Ask About Adherence is a blog series featuring Q&A’s with experts in medication adherence. In this post, we speak with Bruce Stuart, PhD, executive director of the Peter Lamy Center for Drug Therapy...
Read More
Burden on Patients: 5 Questions on Access to Diabetes Medicines in Health Exchange Plans

Patients, especially those suffering from chronic conditions, deserve access to the medicines they need to live longer, healthier lives. Today, PhRMA released a new fact sheet on access to diabetes...
Read More
Video & Infographic: Developing a new drug is actually harder than rocket science

Prescription medicines save lives and cut health care costs, but conjuring a drug to life is a challenging undertaking – and the science is only getting harder. While it may sound counterintuitive,...
Read More
A New Way to Picture Progress Against Cancer

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
The drug development and approval process is about much more than the final “okay”

A recent Forbes story not only presents an oddly limited look at the U.S.’s drug development process, it also sends a misleading message to America’s patients and health care professionals. “The FDA...
Read More
Who is pushing for price controls? The answer may surprise you

Progress in medical innovation over the past few years has been nothing short of remarkable. A once incurable disease – hepatitis C – now has cure rates above 90 percent. Patients previously...
Read More
Medicare Monday: Growing Body of Research Finds Reduced Mortality After Part D

New research from the University of Illinois at Urbana-Champaign adds to a growing body of literature that finds the implementation of Medicare Part D has played a role in reducing mortality among...
Read More
Week in Review: The Latest from PhRMA

The Value of Biopharmaceutical Innovation: The continued development of new treatments and cures not only contributes valuable knowledge to the research and development process, it also improves...
Read More
From Hope to Cures: The Value of Biopharmaceutical Innovation

Biopharmaceutical innovation means more than helping patients lead longer, healthier, more productive lives. Through the continued development of new treatments and cures, each discovery contributes...
Read More
Ask About Adherence: Q&A with RxEconomics LLC

Ask About Adherence is a blog series featuring Q&A’s with experts in medication adherence. In this post, we speak with RxEconomics president and CEO M. Christopher Roebuck PhD, MBA about medication...
Read More
Putting Patients at the Center of the Clinical Pathways Debate

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
ICYMI: The Wall Street Journal Makes the Case for Sharing Truthful, Non-Misleading Information
By Mit Spears | August 18, 2015
On Friday, The Wall Street Journal editorialized on free speech in the context of sharing scientific and medical information, something critical for the U.S. Food and Drug Administration (FDA). FDA’s...
Read More
Medicare Monday: Fact Checking

In case you missed it, Friday we did some Medicare myth busting in our Fact Check Friday series. Check out the post here: The Truth About Negotiation in Medicare Part D
Read More
Week in Review: The Latest from PhRMA

Fact Check Friday: The myth about there being no negotiation in Medicare Part D looms large. In this week’s Fact Check Friday, we debunk this myth and delve into how large, powerful purchasers...
Read More
Fact Check Friday: The Truth About Negotiation in Medicare Part D

This week on Fact Check Friday, we’re talking about something of an urban legend: that there isn’t any negotiation in Medicare Part D. MYTH: There is no negotiation in Medicare Part D. FACT: ...
Read More
Burden on Patients: 5 Questions on Access to Asthma Medicines in Health Exchange Plans

Patients, especially those suffering from chronic conditions, deserve access to the medicines they need to live longer, healthier lives. Today, PhRMA released a new fact sheet on access to asthma...
Read More
ICYMI: Wall Street Journal and Washington Post Say TPP Should Protect Medical Innovation

In case you missed it, The Wall Street Journal and The Washington Post editorialized yesterday on the Trans-Pacific Partnership (TPP) and the importance of reaching a trade deal that protects U.S....
Read More
Medicare Monday: Research Finds Access to Medicare Prescription Drug Coverage Improved Health Outcomes, Significantly Reducing Depressive Symptoms Among Seniors

Depression in the U.S. affects more than 6.5 million Americans age 65 and older. The Medicare Part D prescription drug benefit provides seniors and people living with disabilities access to...
Read More
Week in Review: The Latest from PhRMA

GAO: Prescription Drugs Are Just 2% of Medicaid Spending: The Government Accountability Office reported that fee-for-service drugs accounted for only 1.7 percent of Medicaid expenditures in 2014....
Read More
Fact Check Friday: The Truth about Spending on Cancer Medicines

This week, as part of our Catalyst blog series: Fact Check Friday, we debunk a myth about cancer care to show that maybe the sky isn’t falling after all. MYTH: Cancer drug costs are unsustainable.
Read More
GAO: Prescription Drugs Are Just 2% of Medicaid Spending

Last week, the Government Accountability Office (GAO) released a detailed look at Medicaid and key issues facing the program. Despite rhetoric about the cost of prescription medicines in Medicaid,...
Read More
The Future of Clinical Pathways

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Then and Now: How Prescription Drug Prices Fall Significantly Over Time

Prescription drug prices fall significantly over time because the marketplace is unlike any other part of the U.S. health care system. Innovator companies invest in pioneering research to bring new...
Read More
Legislative and Legal Action Seeks to Improve Communications with Health Care Professionals to Better Inform Patient Care

July was an active time in healthcare policy, with promising policy developments on Capitol Hill and in the court system regarding the ability of biopharmaceutical companies to share up to date and...
Read More
Medicare Monday: Did You Know Four out of Five Part D Prescriptions Are Generic?

The success of the Medicare Part D program has been well documented, providing seniors and individuals living with disabilities access to affordable prescription drug coverage. Before the...
Read More